Home
Clinical Trials
Prediction of Future Weight C...

Prediction of Future Weight Change With Dopamine Transporter

Last Updated: 2018-04-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-01-01

Study Completion Date

2017-04-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is the re-analyzing study of observational study by Parkinson's Progression Markers Initiative

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Long-Term Dopamine Transporter Imaging and Clinical Assessment of Parkinson's Disease Progression

NCT00134784

Parkinson Disease

COMPLETED PHASE2

Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease

NCT00404170

Parkinson Disease

COMPLETED PHASE2

Study of Brain Imaging With Nuclear Technology in Individuals With Parkinsonian Syndrome

NCT00132626

Parkinson's Disease Parkinsonian Syndrome

COMPLETED PHASE2

Long-Term Vesicular Monoamine Transporter II Imaging and Clinical Assessment of Parkinson's Disease Progression

NCT01556100

Parkinson Disease

COMPLETED PHASE2

Weight Changes in Parkinsonian Patients, Treated With Deep Brain Stimulation

NCT00221793

Parkinson Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Weight Change, Body

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

I-123 FP-CIT Single photon emission tomography

Brain scan for dopamine transporter

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* males or females with their age of 30 years or older at screening

Exclusion Criteria

* subjects with a neurological disorder, a first degree relative with idiopathic PD, Montreal Cognitive Assessment score of 26 or less, medications that might interfere with DAT SPECT scans, anticoagulants that might preclude safe completion of the lumbar puncture, or investigational drugs, and a condition that precludes the safe performance of routine lumbar puncture

Minimum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes